Ypsomed and BD Collaborate to Advance Self-Injection Systems for High-Viscosity Biologics
Ypsomed (SIX: YPSN) announced a strategic collaboration with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, to advance self-injection solutions for high-viscosity biologic drugs. In a joint project, Ypsomed and BD have streamlined integration of the BD Neopak XtraFlow Glass Prefillable Syringe with Ypsomed’s YpsoMate 2.25 autoinjector platform, addressing current limitations by enabling the delivery of higher viscosity (>15cP) biologic drugs in an autoinjector format.
Designed to flow beyond limits
The BD Neopak XtraFlow Glass Prefillable Syringe is BD’s latest portfolio addition, featuring a shorter, 8-millimetre needle length and thinner wall cannula to optimise subcutaneous delivery of higher viscosity drug profiles. This improvement allows pharmaceutical developers to break design barriers, enhancing flow and usability beyond today’s limits versus a standard half-inch needle1,2,3. This solution is a part of the BD Neopak Glass Prefillable Syringe Platform, which is designed to address key development needs for biologic drugs.
To support this innovation, Ypsomed is expanding its YpsoMate 2.25 two-step autoinjector platform to accommodate the new syringe format. This includes adapting parts of the autoinjector for the shorter needle, qualifying tooling and assembly, and performing extensive technical testing to ensure reliability. The YpsoMate autoinjector device is handled in two steps: simply remove the cap and push it on the skin, designed so that people with impaired grip or vision can administer their medication easily and safely.
Supporting our pharmaceutical partners to de-risk and accelerate combination product development
“We are excited to welcome the first pharmaceutical customers to experience the benefits of the BD Neopak XtraFlow Glass Prefillable Syringe with the YpsoMate 2.25 autoinjector. This collaboration underscores our commitment to enhancing patient care through innovative drug delivery solutions,” said Ulrike Bauer, chief business officer of Ypsomed Delivery Systems.
“Cross-supplier collaborations are vital in today’s pharmaceutical ecosystem. These partnerships can help drive innovation and ensure that systems work by design and over lifecycles, allowing our pharmaceutical partners to get life-saving therapies to patients faster,” said Patrick Jeukenne, worldwide president of BD Medical – Pharmaceutical Systems.
BD and Ypsomed are key leaders in drug delivery, enabling the administration of chronic condition therapeutics such as GLP-1s, antibodies, and other next-generation formulations. Combining BD’s robust syringe platform technology with Ypsomed’s leading autoinjector platform, this collaboration leverages shared expertise to deliver reliable device systems.
